05/16/2017

NCCN has published updates to the NCCN Guidelines® and NCCN Compendium® for Non-Small Cell Lung Cancer.

NCCN has published updates to the NCCN Guidelines_® and NCCN Compendium^® for Non-Small Cell Lung Cancer. These NCCN Guidelines^® are currently available as Version 6.2017. 

• ALK Rearrangement Positive Metastatic Non-Small Cell Lung Cancer (NSCL-21)
  • Asymptomatic progression; Symptomatic progression - brain or multiple systemic lesions: Brigatinib added as an option for subsequent therapy (category 2A).
  • Footnote "rr" modified: Patients who are intolerant to crizotinib may be switched to ceritinib, alectinib, or brigatinib.
  • Footnote "tt" added: Alectinib or brigatinib are treatment options for patients with ALK-positive metastatic NSCLC that have progressed on crizotinib.
• The Discussion section has been updated to reflect the changes in the guidelines. (MS-1)

*For your reference, the previous update (Version 5.2017) to the NCCN Guidelines for Non-Small Cell Lung Cancer, published on March 16, 2017, is available at the following link: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium®), the NCCN Biomarkers Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.